143 related articles for article (PubMed ID: 36883864)
1. Potential drug candidates as P-glycoprotein inhibitors to reverse multidrug resistance in cancer: an
Ibrahim MAA; Abdeljawaad KAA; Jaragh-Alhadad LA; Oraby HF; Atia MAM; Alzahrani OR; Mekhemer GAH; Moustafa MF; Shawky AM; Sidhom PA; Abdelrahman AHM
J Biomol Struct Dyn; 2023; 41(23):13977-13992. PubMed ID: 36883864
[TBL] [Abstract][Full Text] [Related]
2. Exploring Natural Product Activity and Species Source Candidates for Hunting ABCB1 Transporter Inhibitors: An In Silico Drug Discovery Study.
Ibrahim MAA; Abdeljawaad KAA; Abdelrahman AHM; Jaragh-Alhadad LA; Oraby HF; Elkaeed EB; Mekhemer GAH; Gabr GA; Shawky AM; Sidhom PA; Soliman MES; Moustafa MF; Paré PW; Hegazy MF
Molecules; 2022 May; 27(10):. PubMed ID: 35630581
[TBL] [Abstract][Full Text] [Related]
3. Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study.
Ibrahim MAA; Badr EAA; Abdelrahman AHM; Almansour NM; Shawky AM; Mekhemer GAH; Alrumaihi F; Moustafa MF; Atia MAM
Cell Biochem Biophys; 2021 Jun; 79(2):189-200. PubMed ID: 33954893
[TBL] [Abstract][Full Text] [Related]
4. SuperNatural inhibitors to reverse multidrug resistance emerged by ABCB1 transporter: Database mining, lipid-mediated molecular dynamics, and pharmacokinetics study.
Ibrahim MAA; Abdeljawaad KAA; Abdelrahman AHM; Abdelhamid MMH; Naeem MA; Mekhemer GAH; Sidhom PA; Sayed SRM; Paré PW; Hegazy MF
PLoS One; 2023; 18(7):e0288919. PubMed ID: 37494356
[TBL] [Abstract][Full Text] [Related]
5. Naturally occurring plant-based anticancerous candidates as prospective ABCG2 inhibitors: an in silico drug discovery study.
Ibrahim MAA; Abdelrahman AHM; Badr EAA; Almansour NM; Alzahrani OR; Ahmed MN; Soliman MES; Naeem MA; Shawky AM; Sidhom PA; Mekhemer GAH; Atia MAM
Mol Divers; 2022 Dec; 26(6):3255-3277. PubMed ID: 35224675
[TBL] [Abstract][Full Text] [Related]
6.
Almansour NM; Abdelrahman AHM; Ismail Fagiree E; Ibrahim MAA
J Biomol Struct Dyn; 2023; 41(16):7651-7664. PubMed ID: 36120948
[TBL] [Abstract][Full Text] [Related]
7. Computational binding affinity and molecular dynamic characterization of annonaceous acetogenins at nucleotide binding domain (NBD) of multi-drug resistance ATP-binding cassette sub-family B member 1 (ABCB1).
Manoharan JP; Nirmala Karunakaran K; Vidyalakshmi S; Dhananjayan K
J Biomol Struct Dyn; 2023 Feb; 41(3):821-832. PubMed ID: 34907862
[TBL] [Abstract][Full Text] [Related]
8. In Silico Targeting Human Multidrug Transporter ABCG2 in Breast Cancer: Database Screening, Molecular Docking, and Molecular Dynamics Study.
Ibrahim MAA; Badr EAA; Abdelrahman AHM; Almansour NM; Mekhemer GAH; Shawky AM; Moustafa MF; Atia MAM
Mol Inform; 2022 Feb; 41(2):e2060039. PubMed ID: 34491628
[TBL] [Abstract][Full Text] [Related]
9. In-Silico Mining of the Toxins Database (T3DB) towards Hunting Prospective Candidates as ABCB1 Inhibitors: Integrated Molecular Docking and Lipid Bilayer-Enhanced Molecular Dynamics Study.
Ibrahim MAA; Abdeljawaad KAA; Abdelrahman AHM; Sidhom PA; Tawfeek AM; Mekhemer GAH; Abd El-Rahman MK; Dabbish E; Shoeib T
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513931
[TBL] [Abstract][Full Text] [Related]
10. Isopetasin and S-isopetasin as novel P-glycoprotein inhibitors against multidrug-resistant cancer cells.
Abdelfatah S; Böckers M; Asensio M; Kadioglu O; Klinger A; Fleischer E; Efferth T
Phytomedicine; 2021 Jun; 86():153196. PubMed ID: 32229058
[TBL] [Abstract][Full Text] [Related]
11. Chemical molecular-based approach to overcome multidrug resistance in cancer by targeting P-glycoprotein (P-gp).
Zhang H; Xu H; Ashby CR; Assaraf YG; Chen ZS; Liu HM
Med Res Rev; 2021 Jan; 41(1):525-555. PubMed ID: 33047304
[TBL] [Abstract][Full Text] [Related]
12. The Effects of Traditional Chinese Medicine on P-Glycoprotein-Mediated Multidrug Resistance and Approaches for Studying the Herb-P-Glycoprotein Interactions.
Cao Y; Shi Y; Cai Y; Hong Z; Chai Y
Drug Metab Dispos; 2020 Oct; 48(10):972-979. PubMed ID: 32816867
[TBL] [Abstract][Full Text] [Related]
13. Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo.
De Vera AA; Gupta P; Lei Z; Liao D; Narayanan S; Teng Q; Reznik SE; Chen ZS
Cancer Lett; 2019 Feb; 442():91-103. PubMed ID: 30391357
[TBL] [Abstract][Full Text] [Related]
14. Study on reversal of ABCB1 mediated multidrug resistance in Colon cancer by acetogenins: An
Jeevitha Priya M; Vidyalakshmi S; Rajeswari M
J Biomol Struct Dyn; 2022 Jun; 40(9):4273-4284. PubMed ID: 33280531
[TBL] [Abstract][Full Text] [Related]
15. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
16. Overcoming vincristine resistance in cancer: Computational design and discovery of piperine-inspired P-glycoprotein inhibitors.
Syed SB; Lin SY; Arya H; Fu IH; Yeh TK; Charles MRC; Periyasamy L; Hsieh HP; Coumar MS
Chem Biol Drug Des; 2021 Jan; 97(1):51-66. PubMed ID: 32633857
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and Characterization of Bodipy-FL-Cyclosporine A as a Substrate for Multidrug Resistance-Linked P-Glycoprotein (ABCB1).
Sajid A; Raju N; Lusvarghi S; Vahedi S; Swenson RE; Ambudkar SV
Drug Metab Dispos; 2019 Oct; 47(10):1013-1023. PubMed ID: 31371421
[TBL] [Abstract][Full Text] [Related]
18. A novel flavonoid from Fissistigma cupreonitens, 5‑hydroxy‑7,8‑dimethoxyflavanone, competitively inhibited the efflux function of human P-glycoprotein and reversed cancer multi-drug resistance.
Teng YN; Lin KI; Lin YC; Thang TD; Lan YH; Hung CC
Phytomedicine; 2021 May; 85():153528. PubMed ID: 33735724
[TBL] [Abstract][Full Text] [Related]
19. Wilforine resensitizes multidrug resistant cancer cells via competitive inhibition of P-glycoprotein.
Chang YT; Lin YC; Sun L; Liao WC; Wang CCN; Chou CY; Morris-Natschke SL; Lee KH; Hung CC
Phytomedicine; 2020 Jun; 71():153239. PubMed ID: 32447245
[TBL] [Abstract][Full Text] [Related]
20. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
